Jagsonpal Pharmaceuticals quarterly results

·Pharma & HealthChart ›
Q2 FY27 · Jul–Sep 2026
₹ croreQ2 FY27Q2 FY26Change
Revenue81.474.5+9.3%
EBITDA16.816.4+2.0%
EBITDA margin20.6%22.1%−1.5 pts
Profit before tax16.816.8+0.1%
Net profit12.612.6+0.1%
EPS₹1.91₹1.88+1.6%

Every quarter

₹ crore except per share
Tap a line for its trendQ2 FY27Sep 2026Q1 FY27Jun 2026Q4 FY26Mar 2026Q3 FY26Dec 2025Q2 FY26Sep 2025Q1 FY26Jun 2025Q4 FY25Mar 2025Q3 FY25Dec 2024Q2 FY25Sep 2024Q1 FY25Jun 2024Q4 FY24Mar 2024Q3 FY24Dec 2023Earlier quartersAlpha Plus
81.482.264.272.974.575.658.674.074.761.443.547.2
Earlier quartersEvery year the company has filed comes with Alpha Plus.
2.22.83.23.03.02.82.82.31.71.42.52.5
83.685.167.475.977.578.461.376.376.362.946.049.8
Expenses
4.74.93.04.03.85.33.55.35.24.43.85.9
25.326.119.922.823.822.717.521.122.020.012.114.2
−0.8−2.30.9−0.3−0.4−1.10.70.1−0.9−2.11.8−0.3
22.022.815.517.618.219.416.618.116.714.711.411.6
0.30.30.30.30.30.30.30.30.20.20.20.2
1.72.12.32.42.42.42.32.42.31.10.40.4
13.413.613.712.612.615.011.613.615.414.211.712.5
66.567.455.659.360.764.052.460.961.052.541.444.5
16.817.211.216.316.414.28.715.816.310.22.73.4
15.115.18.813.914.011.96.413.413.99.22.33.0
Profit
17.117.711.816.616.814.48.915.515.410.44.55.3
−0.20.00.0−2.10.00.0−0.223.20.0−3.30.00.0
16.817.711.814.516.814.48.738.715.47.14.55.3
4.04.22.53.73.83.21.28.12.71.61.01.4
0.20.30.5−0.20.40.50.9−1.41.20.2−0.0−0.1
4.24.53.03.64.23.62.16.73.91.81.01.3
12.613.28.811.012.610.86.632.011.55.33.54.0
12.613.28.811.012.610.86.632.011.55.33.54.0
−0.20.10.10.00.20.1−0.30.10.5−0.0−0.20.1
12.413.38.911.012.710.96.332.112.05.33.44.1
Per share
₹1.91₹2.00₹1.25₹1.67₹1.88₹1.60₹0.98₹4.74₹4.29₹1.94₹1.31₹1.48
₹1.87₹1.98₹1.21₹1.65₹1.87₹1.58₹0.98₹4.74₹4.25₹1.93₹1.31₹1.47
Other comprehensive income — detail
−0.20.10.10.00.20.1−0.3—————
−0.30.10.10.00.20.1−0.40.10.7−0.1−0.30.2
−0.10.00.00.00.10.0−0.1—————
———————0.00.2−0.0−0.10.0
Per share — as-filed variants
₹1.91₹2.00₹1.25₹1.67₹1.88₹1.60₹0.98₹4.74₹4.29₹1.94₹1.31₹1.48
₹1.87₹1.98₹1.21₹1.65₹1.87₹1.58₹0.98₹4.74₹4.25₹1.93₹1.31₹1.47
Regulatory disclosures — filed alongside, not part of the P&L
5.4—3.1—3.9—6.8—————
Derived — gross profit (revenue − materials − purchases − Δ inventories)
52.253.640.446.547.248.736.847.548.339.125.827.5
64.1%65.2%63.0%63.7%63.4%64.4%62.9%64.2%64.7%63.7%59.4%58.2%
Adjusted (ex-exceptional items) — derived
17.117.711.816.616.814.48.915.515.410.44.55.3
−0.20.00.0−2.10.00.0−0.223.20.0−3.30.00.0
12.813.28.812.512.610.86.712.811.57.83.54.0
₹1.94₹2.00₹1.25₹1.91₹1.88₹1.60₹1.00₹1.90₹4.29₹2.84₹1.31₹1.48
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersAMRUTANJANNGLFINESYNCOMFHESTERBIOSIGACHILINCOLNWINDLASMcap ₹1,547 Cr
View
In ₹ Crore except Per Share
3 Months Ending
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Revenue from Operations47.243.561.474.774.058.675.674.572.964.282.281.4
Other Income2.52.51.41.72.32.82.83.03.03.22.82.2
Total Income49.846.062.976.376.361.378.477.575.967.485.183.6
Expenses
+ Cost of Materials Consumed5.93.84.45.25.33.55.33.84.03.04.94.7
+ Purchases of Stock-in-Trade14.212.120.022.021.117.522.723.822.819.926.125.3
+ Changes in Inventories-0.31.8-2.1-0.90.10.7-1.1-0.4-0.30.9-2.3-0.8
+ Employee Benefit Expense11.611.414.716.718.116.619.418.217.615.522.822.0
+ Finance Costs0.20.20.20.20.30.30.30.30.30.30.30.3
+ Depreciation & Amortisation0.40.41.12.32.42.32.42.42.42.32.11.7
+ Other Expenses12.511.714.215.413.611.615.012.612.613.713.613.4
Total Expenses44.541.452.561.060.952.464.060.759.355.667.466.5
EBITDA3.42.710.216.315.88.714.216.416.311.217.216.8
EBIT3.02.39.213.913.46.411.914.013.98.815.115.1
Profit
PBT before Exceptional Items5.34.510.415.415.58.914.416.816.611.817.717.1
+ Exceptional Items0.00.0-3.30.023.2-0.20.00.0-2.10.00.0-0.2
Pretax Income5.34.57.115.438.78.714.416.814.511.817.716.8
+ Current Tax1.41.01.62.78.11.23.23.83.72.54.24.0
+ Deferred Tax-0.1-0.00.21.2-1.40.90.50.4-0.20.50.30.2
Tax Expense1.31.01.83.96.72.13.64.23.63.04.54.2
Net Income4.03.55.311.532.06.610.812.611.08.813.212.6
+ Net Income — Continuing Ops4.03.55.311.532.06.610.812.611.08.813.212.6
+ Other Comprehensive Income0.1-0.2-0.00.50.1-0.30.10.20.00.10.1-0.2
Total Comprehensive Income4.13.45.312.032.16.310.912.711.08.913.312.4
Per Share
Basic EPS1.481.311.944.294.740.981.601.881.671.252.001.91
Diluted EPS1.471.311.934.254.740.981.581.871.651.211.981.87
Other Comprehensive Income — detail
+ Other Comprehensive Income—————-0.30.10.20.00.10.1-0.2
+ Items NOT to be Reclassified to P&L0.2-0.3-0.10.70.1-0.40.10.20.00.10.1-0.3
+ Tax on Items NOT to be Reclassified—————-0.10.00.10.00.00.0-0.1
+ Tax on Items NOT to be Reclassified — alt tag0.0-0.1-0.00.20.0———————
Per Share — as-filed variants
Basic EPS — Continuing Operations1.481.311.944.294.740.981.601.881.671.252.001.91
Diluted EPS — Continuing Operations1.471.311.934.254.740.981.581.871.651.211.981.87
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period—————6.8—3.9—3.1—5.4
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit27.525.839.148.347.536.848.747.246.540.453.652.2
Gross Margin %58.2159.3863.7064.7164.1862.9164.3963.4463.7462.9865.1964.13
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)5.34.510.415.415.58.914.416.816.611.817.717.1
− Exceptional Items (reconciliation)0.00.0-3.30.023.2-0.20.00.0-2.10.00.0-0.2
Net Income Adj (tax-effected)4.03.57.811.512.86.710.812.612.58.813.212.8
EPS Adj1.481.312.844.291.901.001.601.881.911.252.001.94
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital13.113.213.213.213.213.313.313.313.413.413.213.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q2 FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Jagsonpal Pharmaceuticals Q2 FY27 results (July–September 2026)

Filed with NSE on Wednesday, 28 October 2026 at 6:13 pm IST

Jagsonpal Pharmaceuticals (NSE: JAGSNPHARM) reported its Q2 FY27 results (July–September 2026) on Wednesday, 28 October 2026 at 6:13 pm IST. Consolidated net profit was ₹12.6 crore, up 0.1% from ₹12.6 crore in Q2 FY26 and down 4.5% from ₹13.2 crore in Q1 FY27. Revenue from operations was ₹81.4 crore, up 9.3% year on year and down 1.0% from the previous quarter.

Q2 FY26 results (a year earlier)
3 November 2025
Q3 FY27 results due by
14 February 2027

Q2 FY27 at a glance · consolidated

Net profit
₹12.6 Cr+0.1% vs Q2 FY26−4.5% vs Q1 FY27
Revenue from operations
₹81.4 Cr+9.3% vs Q2 FY26−1.0% vs Q1 FY27
Operating margin (EBIT)
18.5%−0.3 pts vs Q2 FY26+0.2 pts vs Q1 FY27EBIT ₹15.1 Cr
EBITDA
₹16.8 Cr+2.0% vs Q2 FY26−2.7% vs Q1 FY27margin 20.6%
Earnings per share (basic)
₹1.91+1.6% vs Q2 FY26−4.5% vs Q1 FY27
Net profit margin
15.5%−1.4 pts vs Q2 FY26−0.6 pts vs Q1 FY27

Questions

What was Jagsonpal Pharmaceuticals' net profit in Q2 FY27?

Consolidated net profit was ₹12.6 crore, up 0.1% from ₹12.6 crore in Q2 FY26 and down 4.5% from ₹13.2 crore in Q1 FY27.

What was Jagsonpal Pharmaceuticals' revenue in Q2 FY27?

Revenue from operations was ₹81.4 crore, up 9.3% year on year and down 1.0% from the previous quarter.

What was Jagsonpal Pharmaceuticals' EPS in Q2 FY27?

Basic earnings per share were ₹1.91, against ₹1.88 in Q2 FY26.

How were Jagsonpal Pharmaceuticals' Q2 FY27 results?

Both grew from a year earlier: net profit was up 0.1% at ₹12.6 crore and revenue was up 9.3% at ₹81.4 crore. The operating margin was 18.5%, down 0.3 percentage points from 18.9% a year earlier. Against Q1 FY27, net profit was down 4.5% and revenue down 1.0%.

What was Jagsonpal Pharmaceuticals' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹15.1 crore, a margin of 18.5%, against 18.4% in Q1 FY27 and 18.9% in Q2 FY26. EBITDA was ₹16.8 crore, 20.6% of revenue.

What was Jagsonpal Pharmaceuticals' net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹25.8 crore, up 10.3% from ₹23.4 crore in the same months a year earlier. Revenue from operations was ₹164 crore, up 9.0%.

What is Jagsonpal Pharmaceuticals' net profit margin?

Jagsonpal Pharmaceuticals' net profit margin was 15.5% in Q2 FY27 (net profit as a share of revenue from operations), against 16.9% in Q2 FY26 (down 1.4 percentage points). For FY26 as a whole it was 15.0%.

What was Jagsonpal Pharmaceuticals' net profit in FY26?

Consolidated net profit was ₹43.1 crore in FY26 (April 2025–March 2026), down 22.2% from ₹55.4 crore in FY25. It was ₹22.5 crore in FY24 and ₹26.7 crore in FY23: up 61.2% over three years, 17.3% a year on average.

What was Jagsonpal Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹287 crore in FY26 (April 2025–March 2026), up 6.9% from ₹269 crore in FY25. It was ₹209 crore in FY24 and ₹237 crore in FY23: up 21.3% over three years, 6.7% a year on average.

How has Jagsonpal Pharmaceuticals' profit changed over the last four quarters?

Net profit by quarter: ₹11 crore in Q3 FY26, ₹8.8 crore in Q4 FY26, ₹13.2 crore in Q1 FY27 and ₹12.6 crore in Q2 FY27. That is ₹45.5 crore over the four quarters, down 26.6% from ₹61.9 crore in the four quarters before. Revenue from operations: ₹72.9 crore, ₹64.2 crore, ₹82.2 crore and ₹81.4 crore.

When did Jagsonpal Pharmaceuticals announce its Q2 FY27 results?

On Wednesday, 28 October 2026 at 6:13 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 3 November 2025.

When will Jagsonpal Pharmaceuticals announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Jagsonpal Pharmaceuticals figures come from?

From Jagsonpal Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 28 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.